The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

EDITORIAL

Absence of proof or proof of absence? The risk of underpowered studies in cardiovascular medicine

EuroIntervention 2018;14:727-728. DOI: 10.4244/EIJV14I7A126

1. Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA; 2. Bristol Heart Institute, University of Bristol, School of Clinical Sciences, Bristol, United Kingdom; 3. University of Oxford, Oxford, United Kingdom


In this issue of EuroIntervention Kjøller-Hansen and colleagues report the results of a post hoc analysis of the SORT OUT II trial comparing the 10-year rate of a composite outcome of death, myocardial infarction and repeat revascularisation between patients receiving a single drug-eluting stent in the proximal left anterior descending (LAD) vs. non-proximal LAD1. The authors report no difference between the two groups (HR 0.82, 95% CI: 0.65-1.03).

The analysis has some limitations. The definition used by the authors is somewhat arbitrary and difficult to understand: why not compare LAD vs. non-LAD lesions? Why group the distal LAD with ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Is the proximal left anterior descending coronary artery segment justifiably considered as the last frontier for stenting?